Drug Profile
Bezuclastinib - Cogent Biosciences
Alternative Names: CGT 9486; PLX 9486Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Plexxikon
- Developer Cogent Biosciences; Plexxikon
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal stromal tumours
- Phase II Systemic mastocytosis
- Phase I/II Solid tumours
Most Recent Events
- 23 Feb 2024 Efficacy and pharmacodynamics data from a part 1a of phase II SUMMIT trial in Systemic mastocytosis presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 22 Feb 2024 Efficacy, adverse event and pharmacodynamics data from a part 1b of phase II SUMMIT trial in Systemic mastocytosis released by Cogent Biosciences
- 11 Dec 2023 Efficacy, adverse events and biomarker data from the phase II APEX trial in Systemic mastocytosis released by Cogent Biosciences